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Background: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has
demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown
evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an
anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus
standard of care (SoC) in R/M HNSCC patients.
Patients and methods: Patients were randomly assigned to receive 1 : 1 : 1 durvalumab (10 mg/kg every 2 weeks
[q2w]), durvalumab plus tremelimumab (durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w  4, then
durvalumab 10 mg/kg q2w), or SoC (cetuximab, a taxane, methotrexate, or a fluoropyrimidine). The primary end
points were overall survival (OS) for durvalumab versus SoC, and OS for durvalumab plus tremelimumab versus SoC.
Secondary end points included progression-free survival (PFS), objective response rate, and duration of response.
Results: Patients were randomly assigned to receive durvalumab (n ¼ 240), durvalumab plus tremelimumab (n ¼ 247), or
SoC (n ¼ 249). No statistically significant improvements in OS were observed for durvalumab versus SoC [hazard ratio (HR):
0.88; 95% confidence interval (CI): 0.72e1.08; P ¼ 0.20] or durvalumab plus tremelimumab versus SoC (HR: 1.04; 95% CI:
0.85e1.26; P ¼ 0.76). The 12-month survival rates (95% CI) were 37.0% (30.9e43.1), 30.4% (24.7e36.3), and 30.5% (24.7
e36.4) for durvalumab, durvalumab plus tremelimumab, and SoC, respectively. Treatment-related adverse events (trAEs)
were consistent with previous reports. The most common trAEs (any grade) were hypothyroidism for durvalumab and
durvalumab plus tremelimumab (11.4% and 12.2%, respectively), and anemia (17.5%) for SoC. Grade 3 trAE rates were
10.1%, 16.3%, and 24.2% for durvalumab, durvalumab plus tremelimumab, and SoC, respectively.
Conclusion: There were no statistically significant differences in OS for durvalumab or durvalumab plus tremelimumab
versus SoC. However, higher survival rates at 12 to 24 months and response rates demonstrate clinical activity for
durvalumab.
Trial registration: ClinicalTrials.gov: NCT02369874.
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R. L. Ferris et al. Annals of OncologyINTRODUCTION HNSCC studies, served as the rationale to evaluate dur-Head and neck squamous cell carcinoma (HNSCC) is
among the 10 most common cancers worldwide, with
increasing incidence.1 Approximately 10% of patients with
HNSCC will be diagnosed with metastatic disease, and
even when treated early, around half will have disease
recurrence.2,3 The platinum-based doublet chemotherapy
with cetuximab regimen has been the most widely-used
therapy and considered standard of care (SoC) since it
was proven effective in 2007 for recurrent/metastatic
(R/M) HNSCC in the first-line setting.3,4 However, patients
typically progress even after aggressive first-line therapy,
and, until recently, the available options (e.g. cetuximab,
methotrexate, and taxanes) have delivered limited survival
benefits.3
Durvalumab is an immunotherapeutic agent that blocks
the interaction between programmed cell death ligand 1
(PD-L1) and its receptors.5 Durvalumab demonstrated
encouraging response rates and duration of response (DoR)
with a manageable safety profile in patients with HNSCC.6
Although monotherapy agents that block the programmed
cell death protein 1 (PD-1)/PD-L1 axis have shown clinical
activity, immunotherapy combinations have the potential
to improve upon monotherapy activity.7e9 Cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and PD-L1/PD-1
pathways have largely non-redundant roles, suggesting
that blockade of both could have additive or synergistic
effects.10 Indeed, the combination of durvalumab and
tremelimumab, an anti-CTLA-4 monoclonal antibody, was
explored based on improved efficacy over monotherapy in
other solid tumor types.7 This observation, in addition to
the activity demonstrated by durvalumab in earlier R/MEnrolled: N =
Randomized: N
Received treatment: n = 246
Allocated to durvalumab + tremelimumab: N = 247
aPatients remaining on treatment n = 14
Analyzed
Full analysis set: n = 247
Safety analysis set: n = 246
Analyzed
Full analysis set: n = 240
Safety analysis set: n = 237
Discontinued: n = 232
Did not receive treatment: n = 1
Received treatment: n = 237
Allocated to durvalumab: N 
Did not receive treatment: n 
– Subject decision: n = 7
– Adverse event: n = 36
– Condition under investigation worsened: n = 180
– Patient lost to follow-up: n = 1
– Other: n = 8
aPatients remaining on treatme
Discontinued: n = 217
– Subject decision: n = 9
– Adverse event: n = 22
– Condition under investigation 
– Patient lost to follow-up: n = 2
– Development of study-specific
– Other: n = 2
Figure 1. CONSORT diagram.
a As of 10 September 2018.
Volume 31 - Issue 7 - 2020valumab and tremelimumab in patients with R/M HNSCC.
Several studies, including the EAGLE study, were initiated to
evaluate combination immunotherapy regimens in various
patient groups.11,12 The EAGLE study was the first phase III
study to investigate durvalumab and tremelimumab in pa-
tients with R/M HNSCC who had progressed after platinum-
based therapy.
During the conduct of the EAGLE study, anti-PD-1
monoclonal antibodies were approved for use for R/M
HNSCC progression following a platinum-based regimen.
Treatment with these immunotherapies resulted in a me-
dian overall survival (OS) of 7.5e8.4 months.13,14 These
immunotherapies are now recommended for second-line
treatment as monotherapies for patients with R/M
HNSCC.3,13,14 More recently, immunotherapy alone or in
combination with platinum-based chemotherapy has
shown improvements in OS in the first-line setting,
underscoring the clinical utility of immunotherapy in
HNSCC.15
Here, we report the results of the randomized phase III
EAGLE trial evaluating durvalumab and durvalumab plus
tremelimumab versus SoC therapies in patients with R/M
HNSCC who have progressed following a platinum-
containing regimen.METHODS
Study design and conduct
The study was conducted at 156 sites globally in accordance
with ethical principles originating from the Declaration of
Helsinki and consistent with International Conference on 1163
 = 736
Excluded: n = 427
Analyzed
Full analysis set: n = 249
Safety analysis set: n = 240
= 240 Allocated to standard of care: N = 249
Received treatment: n = 240
– Paclitaxel: n = 92
– Docetaxel: n = 27
– Cetuximab: n = 89
– Methotrexate: n = 36
– Fluoropyrimidine regimen: n = 5
Did not receive treatment: n = 9
= 3
nt n = 20
worsened: n = 179
 discontinuation criteria: n = 3
Patients remaining on treatment n = 0
Discontinued: n = 240
– Subject decision: n = 23
– Adverse event: n = 23
– Condition under investigation worsened: n = 189
– Severe non-compliance to protocol: n = 1
– Other: n = 4
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Table 1. Baseline demographics and clinical characteristics in the full
analysis set
Durvalumab
(n [ 240)
Durvalumab D
tremelimumab
(n [ 247)
Standard of
care
(n [ 249)
Median age, years (range) 59.0 (24e84) 61.0 (23e81) 61.0 (22e82)
Male, n (%) 202 (84.2) 209 (84.6) 207 (83.1)
Race, n (%) n ¼ 238 n ¼ 242 n ¼ 240
White 198 (83.2) 204 (84.3) 189 (78.8)
Asian 35 (14.7) 33 (13.6) 45 (18.8)
Other (including black or
African American)
5 (2.1) 5 (2.0) 6 (2.4)
Ethnicity, n (%)
Hispanic or Latino 15 (6.3) 16 (6.6) 13 (5.4)
Nicotine use, n (%)
Current smoker 41 (17.1) 45 (18.2) 56 (22.5)
Former smoker 153 (63.8) 146 (59.1) 140 (56.2)
Never 46 (19.2) 56 (22.7) 53 (21.3)
Other nicotine usea 3 (1.3) 0 2 (0.8)
Primary tumor location,
n (%)
Oral cavity 64 (26.7) 65 (26.3) 61 (24.5)
Oropharynx 92 (38.3) 91 (36.8) 91 (36.5)
Hypopharynx 41 (17.1) 51 (20.6) 37 (14.9)
Larynx 37 (15.4) 33 (13.4) 45 (18.1)
Other 6 (2.5) 7 (2.8) 15 (6.0)
Time from last platinum
therapy, n (%)
n ¼ 227 n ¼ 234 n ¼ 237
6 months 185 (81.5) 195 (83.3) 208 (87.8)
>6 months 42 (18.5) 39 (16.7) 29 (12.2)
ECOG PS, n (%)
0 62 (25.8) 64 (25.9) 79 (31.7)
1 178 (74.2) 183 (74.1) 170 (68.3)
Median number of prior
treatments (range)
1.0 (1e4) 1.0 (1e4) 1.0 (1e4)
Tumor location/HPV
status, n (%)
n ¼ 240 n ¼ 246 n ¼ 249
OPC/positive 30 (12.5) 30 (12.2) 31 (12.4)
OPC/negative 60 (25.0) 58 (23.6) 60 (24.1)
Non-OPC/any HPV 150 (62.5) 158 (64.2) 158 (63.5)
PD-L1 status, n (%)
TC  25% 68 (28.3) 72 (29.1) 72 (28.9)
TC < 25% 172 (71.7) 175 (70.9) 177 (71.1)
Disease extent at baseline,
n (%)
Local/regional recurrence
 distant metastases
221 (92.1) 224 (90.7) 214 (85.9)
Distant metastases only 19 (7.9) 23 (9.3) 35 (14.1)
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance
status; HPV, human papilloma virus; OPC, oropharyngeal cancer; PD-L1, programmed
death ligand 1; TC, tumor cell.
a Including chewing tobacco/oral snuff/sublingual nicotine.
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applicable regulatory requirements, and sponsor’s policy on
Bioethics and Human Biological Samples. Written informed
consent from participants was obtained before performing
any protocol-related procedures.
Randomization was stratified according to PD-L1 expres-
sion, tumor location/human papilloma virus (HPV) status,
and smoking status. PD-L1 expression was centrally
assessed using the VENTANA (Ventana Medical Systems,
Inc., Tuscon, AZ) PD-L1 (SP263) Assay, using a cut-off of
25% tumor cells (TC  25%) with membrane staining for
PD-L1 at any intensity.16 HPV was assessed according to
local standard procedures, including immunohistochemistry,
FISH or polymerase chain reaction.944 https://doi.org/10.1016/j.annonc.2020.04.001Patients were randomly assigned to receive 1 : 1 : 1 dur-
valumab [10 mg/kg every 2 weeks (q2w)], durvalumab plus
tremelimumab [durvalumab 20 mg/kg every 4 weeks (q4w)
plus tremelimumab 1 mg/kg q4w up to four doses, followed
by durvalumab 10 mg/kg q2w], or investigator’s choice of a
single-agent SoC therapy. Each SoC agent (cetuximab,
docetaxel, paclitaxel, methotrexate, 5-fluorouracil, TS-1, or
capecitabine) was dosed and administered according to local
regulations. Treatment continued until confirmed disease
progression, initiation of alternative therapy, or unaccept-
able toxicity.
Recruitment was voluntarily suspended to investigate a
potential increase in bleeding events identified by the in-
dependent data monitoring committee (IDMC), and sites
were notified on 21 September 2016. After a comprehen-
sive evaluation, no causal link between study treatment and
bleeding events was established and the IDMC recom-
mended study continuation. Recruitment resumed on 1
December 2016.Patients
Eligible patients were aged 18 years, had an Eastern
Cooperative Oncology Group performance status (ECOG PS)
of 0 or 1 and histological or cytological confirmed R/M
HNSCC of the oral cavity, oropharynx, hypopharynx, or lar-
ynx not amenable to curative therapy who had progression
or recurrence during or after only one systemic treatment
regimen containing a platinum agent, or progressed within
6 months of the last dose of platinum administered as part
of multimodal therapy of curative intent.Outcomes measurements
The dual primary end points were OS for durvalumab versus
SoC and OS for durvalumab plus tremelimumab versus SoC.
Secondary objectives included 12-, 18-, and 24-month OS
rates as well as progression-free survival (PFS), objective
response rate (ORR), DoR (using investigator assessments
according to RECIST version 1.1), and safety.
The sample size was selected to provide approximately
90% power to demonstrate statistical significance at an
overall 2.5% level (two-sided, allowing for one interim
analysis) if the assumed true treatment effect is a hazard
ratio (HR) of 0.69 for comparison of either durvalumab or
durvalumab plus tremelimumab versus SoC. The intent-to-
treat population (defined as all randomized patients) was
used for efficacy outcome analyses, which were conducted
using a log-rank test stratified by randomization factors, and
a stratified Cox proportional hazards model to estimate
treatment effect. Medians were derived using the Kaplane
Meier method. Safety data were analyzed using the safety
analysis set (defined as all patients receiving 1 doses of
study treatment). Adverse events (AEs) were monitored and
graded by investigators according to National Cancer Insti-
tute Common Terminology Criteria for Adverse Events,
version 4.03. Safety data were periodically reviewed by the
IDMC.Volume 31 - Issue 7 - 2020
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Figure 2. Analyses of planned endpoints in the full analysis set.
(A) KaplaneMeier plot of median OS for durvalumab versus SoC. (B) KaplaneMeier plot of median OS for durvalumab plus tremelimumab versus SoC. (C) KaplaneMeier
plot of duration of response for patients who responded to durvalumab versus SoC. (D) KaplaneMeier plot of duration of response for patients who responded to
durvalumab plus tremelimumab versus SoC.
CI, confidence interval; DoR, duration of response; SoC, standard of care.
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Patient disposition and baseline characteristics
Between 5 November 2015 and 21 July 2017, 736 patients
were randomly assigned to receive either durvalumab
(n ¼ 240), durvalumab plus tremelimumab (n ¼ 247), or
SoC chemotherapy (n ¼ 249; Figure 1). Paclitaxel (36.9%)
and cetuximab (35.7%) were the most frequent choices for
SoC (Figure 1).Volume 31 - Issue 7 - 2020Patient demographics and characteristics were repre-
sentative of the intended patient population and most were
balanced across treatment groups (Table 1). However, there
were more patients in the SoC arm with ECOG PS of 0 and a
higher percentage of patients in the SoC arm had only
distant metastases (no locoregional recurrence) at baseline.
The median age for all patients was 60.0 years, 84.0% were
male, 82.1% were white, and 15.7% were Asian. At baseline,
28.8% of tumor samples had PD-L1 expression of TC  25%.https://doi.org/10.1016/j.annonc.2020.04.001 945
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Figure 2. Continued.
Annals of Oncology R. L. Ferris et al.Of the patients with oropharyngeal cancer (n ¼ 269), 91
were HPV-positive (12.4%). The majority of patients were
former (59.6%) or current (19.3%) smokers.
Efficacy
Data cut-off was 10 September 2018. The median duration
of follow-up was 7.6, 6.3, and 7.8 months for durvalumab,946 https://doi.org/10.1016/j.annonc.2020.04.001durvalumab plus tremelimumab, and SoC, respectively. No
statistically significant difference in OS was observed for
durvalumab versus SoC [HR ¼ 0.88; 95% confidence interval
(CI): 0.72e1.08; P ¼ 0.20] or for durvalumab plus trem-
elimumab versus SoC (HR ¼ 1.04; 95% CI: 0.85e1.26;
P ¼ 0.76) (Figure 2A and B). Treatment effect was analyzed
in several subgroups (Supplementary Figure S1, available atVolume 31 - Issue 7 - 2020
R. L. Ferris et al. Annals of OncologyAnnals of Oncology online). The 12-month survival rate was
higher for durvalumab [37.0% (95% CI: 30.9e43.1)]
compared with SoC [30.5% (95% CI: 24.7e36.4)] and similar
differences were seen at 18 and 24 months (Figure 2A).
There were numerically higher survival rates for durvalumab
plus tremelimumab at 18 and 24 months (Figure 2B).
In patients with tumors having PD-L1 expression of TC
 25%, median OS was 9.8 months (95% CI: 4.3e14.1) for
durvalumab, 4.8 months (95% CI: 3.3e6.4) for durvalumab
plus tremelimumab, and 9.0 months (95% CI: 6.8e11.0) for
SoC. Median OS was 7.6 months (95% CI: 6.2e9.5) for
durvalumab, 7.8 months (95% CI: 5.9e10.3) for durvalumab
plus tremelimumab, and 8.0 months (95% CI: 6.7e8.9) for
SoC for patients with tumors expressing TC < 25%. Evalu-
ating a PD-L1 expression cut-off of TC 1%, OS for both
durvalumab and durvalumab plus tremelimumab did not
differentiate from SoC. However, in the small population of
patients in the <1% TC group, OS was longer for durvalu-
mab than SoC. There was no difference for durvalumab plus
tremelimumab versus SoC in the <1% TC group
(Supplementary Figure S1, available at Annals of Oncology
online).
There was no difference in PFS for durvalumab versus
SoC (HR ¼ 1.02; 95% CI: 0.84e1.25; P ¼ 0.75) or for dur-
valumab plus tremelimumab versus SoC (HR ¼ 1.09; 95% CI:
0.90e1.33; P ¼ 0.54). Median PFS was 2.1 months (95% CI:
1.9e3.0) for the durvalumab arm, 2.0 months (95% CI: 1.9e
2.3) for durvalumab plus tremelimumab, and 3.7 months
(95% CI: 3.1e3.7) for SoC.
ORR (95% CI) was 17.9% (13.3e23.4) for durvalumab,
18.2% (13.6e23.6) for durvalumab plus tremelimumab, and
17.3% (12.8e22.5) for SoC (Figure 2C and D). The only
complete responses were observed in the immunotherapy
arms (n ¼ 6, durvalumab; n ¼ 6, durvalumab plus trem-
elimumab). Median DoR (95% CI) was longer for durvalu-
mab and durvalumab plus tremelimumab versus SoC; 12.9
months (6.9e21.0), 7.4 months (3.6e14.8), and 3.7 months
(2.0e4.2), respectively (Figure 2 C and D). The median time
to response (range) was 3.7 months (1.9e11.4) for durva-
lumab, 2.1 months (1.5e9.1) for durvalumab plus trem-
elimumab, and 1.6 months (1.3e20.3) for SoC.
As the ORR was higher than expected, and notably,
because the median OS for SoC was unexpectedly long
considering historical values and more recent reports, post
hoc analyses were conducted to understand the perfor-
mance of the SoC arm. As noted, there were imbalances in
ECOG PS and patients with only distant metastatic disease
at baseline. A multivariate analysis confirmed that these
were prognostic, and when the primary stratified Cox model
was adjusted for these characteristics, the HR was 0.81 (95%
CI: 0.66e1.00) for durvalumab compared with SoC
(Supplementary Table S1, available at Annals of Oncology
online). Another post hoc analysis evaluated the impact of
subsequent therapy on OS in the SoC arm, and showed that
263 (35.7%) patients from all arms received subsequent
therapy after discontinuation. Overall, the median OS of
patients receiving subsequent immunotherapy was 18.3
months (95% CI: 14.7e22.9), which was longer than theVolume 31 - Issue 7 - 2020median OS for patients who received other subsequent
anticancer therapies [n ¼ 207, 10.8 months (95% CI: 10.1e
12.3)]. Notably, more patients from the SoC arm received
subsequent immunotherapy (n ¼ 38, 15%) than those in
the durvalumab (n ¼ 5, 2.1%) or durvalumab plus trem-
elimumab arms (n ¼ 13, 5.3%).Safety
The median duration of exposure was approximately 3
months for each arm (Supplementary Table S2, available at
Annals of Oncology online). Treatment-related AEs (trAEs) of
any grade occurred in 57.4% in the durvalumab arm, 61.0%
in the durvalumab plus tremelimumab arm, and 82.1% in
the SoC arm (Table 2). Grade 3 trAEs occurred in 24 pa-
tients (10.1%) receiving durvalumab, 40 patients (16.3%)
receiving durvalumab plus tremelimumab, and 58 patients
(24.2%) receiving SoC. Discontinuation attributed to trAEs
occurred in nine patients (3.8%) in the durvalumab arm, 10
(4.1%) in the durvalumab plus tremelimumab arm, and 10
(4.2%) in the SoC arm (Supplementary Table S3, available at
Annals of Oncology online). Any bleeding-related trAEs
were rare (Supplementary information, available at Annals
of Oncology online). Death attributed to trAEs occurred in
four patients in the durvalumab arm, two in the durvalu-
mab plus tremelimumab arm, and none in the SoC arm.
DISCUSSION AND CONCLUSIONS
The study results did not demonstrate a statistically signif-
icant survival benefit for immunotherapy over single-agent
SoC as second-line treatment of patients with R/M
HNSCC. Combining durvalumab with tremelimumab did not
show improvement over durvalumab activity, though it
should be noted that the EAGLE study was not designed for
comparison between durvalumab and durvalumab plus
tremelimumab arms.
Despite the apparent lack of benefit over SoC, durvalu-
mab clinical activity was in line with other checkpoint
blockade agents in this setting.13,14 Although cross-trial
comparisons should be approached with caution, median
OS for durvalumab (7.6 months) was similar to median OS
for nivolumab (7.5 months) and pembrolizumab (8.4
months) in comparable patient populations. Likewise, 12-
month survival rates for all three were similar (durvalu-
mab, 37.0%; nivolumab, 36.0%; pembrolizumab,
37.0%).13,14 Additionally, within the context of the EAGLE
study, there were examples of activity in favor of durvalu-
mab, including complete responders and longer DoR versus
SoC, suggesting that the benefit from durvalumab was more
durable than from SoC. There also seems to be a survival
benefit favoring durvalumab, with 12-, 18-, and 24-month
survival rates being numerically higher in the durvalumab
arm versus the SoC arm.
This study was characterized by an unexpectedly high OS
for the SoC arm with a median of 8.3 months. This outcome
was higher than median OS values for SoC arms reported in
similar studies with PD-1 inhibitors (5.1e6.9 months).13,14
Several potential contributing factors were identified. Onehttps://doi.org/10.1016/j.annonc.2020.04.001 947
Table 2. Incidence of trAEs (‡5% for any grade, ‡2% for grade 3e4 in any arm) in the safety analysis set
Durvalumab (n [ 237) Durvalumab D tremelimumab
(n [ 246)
Standard of care (n [ 240)
Any grade Grade 3e4 Any grade Grade 3e4 Any grade Grade 3e4
Patients with any trAE, n (%) 136 (57.4) 24 (10.1) 150 (61.0) 40 (16.3) 197 (82.1) 58 (24.2)
Alopecia 0 0 0 0 28 (11.7) 0
Anemia 12 (5.1) 0 20 (8.1) 4 (1.6) 42 (17.5) 11 (4.6)
Asthenia 15 (6.3) 1 (0.4) 20 (8.1) 5 (2.0) 32 (13.3) 2 (0.8)
Decreased appetite 12 (5.1) 0 14 (5.7) 2 (0.8) 28 (11.7) 3 (1.3)
Dermatitis acneiform 2 (0.8) 0 2 (0.8) 0 16 (6.7) 0
Diarrhea 14 (5.9) 0 20 (8.1) 2 (0.8) 17 (7.1) 3 (1.3)
Elevated ALT 7 (3.0) 1 (0.4) 10 (4.1) 0 14 (5.8) 1 (0.4)
Elevated GGT 8 (3.4) 1 (0.4) 10 (4.1) 2 (0.8) 12 (5.0) 1 (0.4)
Fatigue 16 (6.8) 2 (0.8) 18 (7.3) 3 (1.1) 26 (10.8) 2 (0.8)
Hypothyroidism 27 (11.4) 0 30 (12.2) 0 0 0
Leukopenia 2 (0.8) 0 9 (3.7) 0 12 (5.0) 4 (1.7)
Mucosal inflammation 0 0 1 (0.4) 0 12 (5.0) 1 (0.4)
Nausea 12 (5.1) 1 (0.4) 10 (4.1) 0 33 (13.8) 0
Neuropathy peripheral 3 (1.3) 1 (0.4) 3 (1.2) 0 20 (8.3) 2 (0.8)
Neutropenia 3 (1.3) 0 11 (4.5) 1 (0.4) 31 (12.9) 12 (5.0)
Pruritus 8 (3.4) 0 20 (8.1) 0 6 (2.5) 0
Rash 15 (6.3) 0 11 (4.5) 0 33 (13.8) 0
Stomatitis 4 (1.7) 1 (0.4) 3 (1.2) 0 23 (9.6) 0
Thrombocytopenia 5 (2.1) 1 (0.4) 11 (4.5) 2 (0.8) 16 (6.7) 1 (0.4)
ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; trAEs, treatment-related adverse events.
Annals of Oncology R. L. Ferris et al.factor, and a key difference between EAGLE and other
studies, is that both paclitaxel and docetaxel were used as
choices for SoC in this study, while only docetaxel was
allowed in other studies. A comparison of paclitaxel and
docetaxel activity within the SoC arm of the EAGLE study
showed a nominal HR of 0.69 (95% CI: 0.44e1.13) in favor
of paclitaxel. Notably, more patients were treated with
paclitaxel than docetaxel. Another factor that commonly
affects assessment of OS is subsequent therapy. A post hoc
analysis showed that patients who received an immuno-
therapy agent after discontinuation of treatment in the
EAGLE study had longer OS. A higher percentage of patients
from the SoC arm went on to receive subsequent immu-
notherapy. Lastly, imbalances were noted in clinical char-
acteristics between the randomized groups, specifically
ECOG PS and patients with metastatic disease only (as
opposed to loco-regional disease with or without metastatic
disease) at baseline. Other imbalances were evaluated, but
none impacted OS and, indeed, both characteristics have
been reported to have a meaningful prognostic impact on
OS in other studies involving patients with R/M HNSCC.17,18
These factors may have confounded the results by creating
a larger proportion of patients with a more favorable
prognosis in the SoC arm and a multivariate analysis
adjusting for these imbalanced factors showed that the
estimated treatment effect improved in favor of immuno-
therapy when accounting for that imbalance. Collectively,
choice of SoC therapy, subsequent therapy, and imbalances
in clinical characteristics provide a possible explanation for
the longer-than-expected OS of the SoC arm.
It is worth noting that a recently published systematic
analysis by the US Food and Drug Administration identi-
fied a trend in disproportionately high early mortality
rates in studies evaluating anti-PD-1 and anti-PD-L1 agents948 https://doi.org/10.1016/j.annonc.2020.04.001against active control arms where authors describe a
crossing of KaplaneMeier OS curves.19 This phenomenon
was also observed in the EAGLE study where a higher
percentage of patients in the immunotherapy arms died
within the first 3 months from randomization. Conversely,
higher survival rates for durvalumab indicates that pa-
tients who live beyond the initial treatment period may be
those most likely to receive benefit. It is therefore critical
to develop a means to identify patients at risk of early
death, which could guide treatment decisions by identi-
fying patients who are optimal candidates for single-agent
immunotherapy.
The safety profile for durvalumab was consistent with
prior data.11,12 The durvalumab plus tremelimumab arm
was likewise consistent with other studies evaluating this
regimen, though grade 3e4 trAEs and the discontinuation
rate were slightly higher than with durvalumab alone.7,11
Following a voluntary recruitment pause initiated to inves-
tigate bleeding AEs, no association between durvalumab or
durvalumab plus tremelimumab and bleeding-related AEs
was found and recruitment was resumed.
In conclusion, although durvalumab showed antitumor
activity and durvalumab and durvalumab plus trem-
elimumab did prove to be tolerable, the primary objectives
of the study were not met. Further biomarker evaluations
are underway in an attempt to understand the clinical ac-
tivity of immune checkpoint inhibition in this setting.
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